The study is being conducted at the University Hospital Tuebingen and supported by the DZNE (German Centre for Neurodegenerative Diseases) and HIH (Hertie Institute for Clinical Brain Research). Additional third-party fundings have been granted from CIN (Centre for Integrative Neuroscience). A sub-study is supported by TEVA Pharmaceutical Industries Ltd. Further sponsors of TREND are ucb and Janssen Pharmaceuticals, Inc. as well as the International Parkinson Fonds.